Laddar...
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
PURPOSE: A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. PATIENTS AND METHODS...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Society of Clinical Oncology
2009
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3646307/ https://ncbi.nlm.nih.gov/pubmed/19487381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.1293 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|